Newsroom | Gilead - Gilead Sciences
View all. This is our global website, intended for visitors seeking information on Gilead’s worldwide business. Some content on this site is not intended for people outside the United States. Visit …
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
Feb 6, 2024 · Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 7% to $3.1 billion in the fourth quarter 2023 compared to the same period in 2022, primarily reflecting higher demand, partially offset by lower average realized price due to channel mix.
Gilead Sciences
For more than 35 years, we've been tackling some of the world’s greatest public health challenges. We've revolutionized HIV treatment and prevention, delivered a cure for hepatitis C and made advancements in therapies for viral diseases and certain cancers.
Gilead Sciences to Acquire MiroBio
Aug 4, 2022 · MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed earlier this week.
Gilead Sciences Announces Fourth Quarter and Full Year 2022 …
Feb 2, 2023 · Fourth Quarter 2022 Financial Results. Total fourth quarter 2022 revenue of $7.4 billion increased 2% compared to the same period in 2021, primarily due to increased sales in Oncology, HIV and hepatitis C virus (“HCV”), partially offset by lower Veklury® (remdesivir) sales.
Gilead Provides Update on Phase 3 EVOKE-01 Study - Gilead …
Jan 22, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
Gilead Sciences Announces Second Quarter 2022 Financial Results
Total second quarter 2022 revenue increased 1% to $6.3 billion compared to the same period in 2021, primarily due to increased sales in HIV and oncology products, offset partially by decreased sales of Veklury® (remdesivir) and hepatitis C virus (“HCV”) products.
Gileads Innovative HIV Treatment Research Pipeline ... - Gilead …
Mar 5, 2024 · In a recent Phase 1b study published in The Lancet HIV, the investigational combination of lenacapavir + teropavimab (GS-5423, TAB) + zinlirvimab (GS-2872, ZAB) demonstrated high efficacy and maintained virologic suppression for …
Gilead Sciences Announces Third Quarter 2022 Financial Results
Oct 27, 2022 · Third Quarter 2022 Financial Results. Total third quarter 2022 revenue decreased 5% to $7.0 billion compared to the same period in 2021, primarily due to lower Veklury® (remdesivir) sales, partially offset by increased sales in HIV and oncology products.
Gilead Sciences Expands Liver Portfolio With Acquisition of …
Feb 12, 2024 · Seladelpar, an investigational treatment for people with PBC, is an oral, selective peroxisomeproliferator-activated receptor delta (PPARδ) agonist shown to regulate critical metabolic and liver disease pathways in indications with high unmet medical need.